Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis.

about

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis.

Item

http://www.wikidata.org/entity/Q55191066

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

Combination Therapy With Ritux ...... Induction in ANCA Vasculitis.

@en

Combination Therapy With Ritux ...... Induction in ANCA Vasculitis.

@nl

type

Item

label

Combination Therapy With Ritux ...... Induction in ANCA Vasculitis.

@en

Combination Therapy With Ritux ...... Induction in ANCA Vasculitis.

@nl

prefLabel

Combination Therapy With Ritux ...... Induction in ANCA Vasculitis.

@en

Combination Therapy With Ritux ...... Induction in ANCA Vasculitis.

@nl

P1476

Combination Therapy With Ritux ...... Induction in ANCA Vasculitis.

@en

P2093

Colleen Dunbar

http://www.w3.org/2001/XMLSchema#string

Frank B Cortazar

http://www.w3.org/2001/XMLSchema#string

John L Niles

http://www.w3.org/2001/XMLSchema#string

Karen Laliberte

http://www.w3.org/2001/XMLSchema#string

Saif A Muhsin

http://www.w3.org/2001/XMLSchema#string

William F Pendergraft

http://www.w3.org/2001/XMLSchema#string

Zachary S Wallace

http://www.w3.org/2001/XMLSchema#string

P2860

2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides

A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group

Damage in the anca-associated vasculitides: long-term data from the European vasculitis study group (EUVAS) therapeutic trials.

Cancer risk after cyclophosphamide treatment in idiopathic membranous nephropathy.

Late-onset neutropenia following rituximab therapy in rheumatic diseases: association with B lymphocyte depletion and infections.

Antiproteinase 3- and antimyeloperoxidase-associated vasculitis.

Rituximab as maintenance therapy for anti-neutrophil cytoplasmic antibody-associated vasculitis

Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis.

Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma.

Rituximab versus cyclophosphamide for ANCA-associated vasculitis.

P304

394-402

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EKIR.2017.11.004

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29725643

http://www.w3.org/2001/XMLSchema#string

P932

5932132

http://www.w3.org/2001/XMLSchema#string